Elutia completes SimpliDerm sale to Cellution for $11M; adds $7.7M net cash

ELUTIA INC.

Closed Aug 17, 2026 sale of Women's Health hADM assets to Cellution Biologics.
Received $7.7M net cash ($8M at close less inventory adjustments); up to $3M contingent milestones over 18 months.
Transaction treated as discontinued operations; estimated pre-tax gain of $4.9M.
Pro forma H1 2026 continuing ops net loss $16.2M ($0.37/share) vs $15.5M reported.
NXT-41x (antibiotic-eluting biomatrix) FDA clearance expected H1 2027; funding secured through launch year 2028.

Featured in Daily 8-K Digest

Selected #4 for 2026-08-21. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.